Pancreatic Cancer Research

Clinical trialPhase 1Unknown

First in Human Study of TORL-2-307-MAB in Participants With Advanced Cancer

A Phase 1, First in Human, Dose-Escalation Study of TORL-2-307-MAB in Participants With Advanced Cancer

Outcome
Outcome unknown
Phase
Phase 1
Status
Unknown
Study type
Interventional
Start
20 January 2022
Listed end
15 December 2025
Enrollment
70 participants
Sites
8
Primary outcomes
Incidence and severity of adverse events and serious adverse events; Maximum Tolerated Dose (MTD); Recommended Phase 2 Dose (RP2D)
Sponsor type
Industry
Results posted
No
Last update
22 October 2024

These fields come from the trial’s registry entry. A summary of its population, design, endpoints and results, each tied to a quote, has not been written for this trial yet.

Ask this document

Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.

Try

Source text

Brief summary public domain (ClinicalTrials.gov)

This first-in-human study will evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of TORL-2-307-MAB in patients with advanced cancer